ETNB Stock News & Analysis | Latest Updates

89bio to Participate in Upcoming Investor Conferences

(NASDAQ:ETNB) SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s management will participate in the following investor conferences during the month of September:

ETNB News

89bio to Participate in Upcoming Investor Conferences

89bio Q1 EPS $(0.49) Beats $(0.50) Estimate

Goldman Sachs Initiates Coverage On 89bio with Neutral Rating, Announces Price Target of $11

Citigroup Initiates Coverage On 89bio with Buy Rating, Announces Price Target of $25

HC Wainwright & Co. Reiterates Buy on 89bio, Lowers Price Target to $21

89bio Q4 2024 GAAP EPS $(1.02) Misses $(0.77) Estimate

89bio Announces Completion Of Enrollment In Phase 3 ENTRUST Trial For Severe Hypertriglyceridemia; Topline Data Expected In H2 2025. Phase 3 ENLIGHTEN Program For MASH Continues Enrollment. Cash And Equivalents Total $440M As Of Dec 31, 2024

89bio Presents New Analyses Evaluating Pegozafermin And Potential Benefit Of Non-Invasive Tests From The ENLIVEN Phase 2b Trial In MASH Patients At AASLD The Liver Meeting 2024

89bio Will Present 48-Week Data From ENLIVEN Phase 2b Pegozafermin Trial In MASH At EASL International Liver Congress

Cantor Fitzgerald Reiterates Overweight on 89bio, Maintains $29 Price Target

HC Wainwright & Co. Reiterates Buy on 89bio, Maintains $29 Price Target

HC Wainwright & Co. Reiterates Buy on 89bio, Maintains $29 Price Target

Analyst Ratings for 89bio

7 Analysts Have This to Say About 89bio

Raymond James Maintains Strong Buy on 89bio, Raises Price Target to $25

89bio Shares Up 29%; Raymond James Raise Price Target From $14 To $25

Hearing RBC Reiterates Buy And $35 Price Target On 89bio; Hearing Firm Says It Believes NASH Data From Akero Should Have Positive Read-Throughs To Probability Of Success Of Co.'s Pegoza Program